TY  - GEN
AU  - Wigginton,J M
AU  - Gruys,E
AU  - Geiselhart,L
AU  - Subleski,J
AU  - Komschlies,K L
AU  - Park,J W
AU  - Wiltrout,T A
AU  - Nagashima,K
AU  - Back,T C
AU  - Wiltrout,R H
TI  - IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
SN  - 0021-9738
PY  - 2001///0809
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Animals
KW  - Antineoplastic Agents
KW  - Apoptosis
KW  - drug effects
KW  - CD8-Positive T-Lymphocytes
KW  - immunology
KW  - Carcinoma, Renal Cell
KW  - blood supply
KW  - Combined Modality Therapy
KW  - Drug Administration Schedule
KW  - Endothelium, Vascular
KW  - Fas Ligand Protein
KW  - Immunologic Factors
KW  - Injections, Intraperitoneal
KW  - Interferon-gamma
KW  - physiology
KW  - Interleukin-12
KW  - Kidney Neoplasms
KW  - Membrane Glycoproteins
KW  - deficiency
KW  - Mice
KW  - Mice, Inbred BALB C
KW  - Mice, Inbred C3H
KW  - Mice, Knockout
KW  - Mice, Mutant Strains
KW  - Neoplasm Metastasis
KW  - Neoplasm Transplantation
KW  - Neovascularization, Pathologic
KW  - drug therapy
KW  - Nephrectomy
KW  - Recombinant Proteins
KW  - Specific Pathogen-Free Organisms
KW  - fas Receptor
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1172/JCI10128
ER  -